Therapies

BioGenCell’s patented, breakthrough lead product BGC101 was designed from the ground up to help patients with blood vessel diseases often seen in the elderly and diabetic populations.

Chronic vascular diseases are by far the major cause of morbidity and mortality that lead to a gradual deterioration of bodily function manifesting as heart attacks, stroke, peripheral vascular disease (PVD) kidney failure, blindness and more.

A dramatically increased risk for the development of vascular disease is related to diabetes which affects more than 350 million people worldwide.

Most of the complications of diabetes are due to blood vessel malfunction. 42% of diabetic patients have at least one major complication, while 10% suffer from severe or end-stage disease, which is one of the most common causes of dialysis, blindness and critical limb ischemia (CLI – the lead reason for limb amputation). The main problem in handling this widespread disease is that existing treatments are of limited effect, causing most patients to succumb to complications and creating an urgent need for effective therapies.

BioGenCell’s lead product BGC101 implements the company’s technology for treating blood vessel diseases that cause multiple organ failure. BGC101 is manufactured from stem cells and culture components extracted from the patient’s own blood and is composed of a significant number of highly viable cells targeted at blood vessel regeneration (endothelial progenitor cells), as well as cells that can self-adjust according to specific needs for the purpose of tissue regeneration (multi-potent adult stem/progenitor cells).

The first disease in the vascular disease pipeline to be targeted by BGC101 is Critical Limb Ischemia the most serious manifestation of PVD. Current best practice treatment for CLI includes artery revascularization by angioplasty or bypass operation. In addition, CLI patients are treated with medications to improve blood flow, reduce blood viscosity, and relieve pain. Despite improvement in these treatments, 25% of CLI patients are defined as ‘no option’ and dunned to amputation.

Our goal is the elimination of the risk of amputation and death for most of them. We want to return the patient from serious disability to functional capacity, free of pain with good quality of life.